에를로티닙과 라파티닙을 사용한 환자에서 발생한 표층점상각막병증

• 영문명: Superficial Punctate Keratoepitheliopathy Under Treatment with Erlotinib and Lapatinib
• 발행기관: 대한안과학회
• 저자명: 오은규 조동현 김미금 위원량,Eun Kyu Oh, MD, Dong Hyun Jo, MD, Mee Kum Kim, MD, PhD, Won Ryang Wee, MD, PhD,
• 간행물 정보: 『대한안과학회지』Ophthalmological Society,volume55,number2, 293~297쪽, 전체 5쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2014.02.15

영문 초록

Purpose: To report the corneal superficial punctate keratoepitheliopathy in 2 patients taking the epidermal growth factor receptor (EGFR) inhibitors, erlotinib and lapatinib, respectively. Case summary: Case 1, who received erlotinib, showed trichomegaly without touching the cornea and diffuse punctate keratoepitheliopathy. Corneal epitheliopathy and the corresponding symptoms resolved after discontinuation of the drug then recurred with reapplication. Case 2 presented diffuse corneal punctate epithelial erosions that developed without any cilia involvement after the patient was administered lapatinib. The visual acuity of both patients was not severely diminished and keratoepitheliopathy was mostly resolved with the treatment of preservative-free artificial tears and autologous serum eye drops. Conclusions: Erlotinib and lapatinib are both likely to cause visually tolerable corneal punctate keratoepitheliopathy which can be resolved with appropriate topical treatment. J Korean Ophthalmol Soc 2014;55(2):293-297

키워드

Cancer treatment, Corneal erosion, Epidermal growth factor